Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

Journal:

Nature Communications

Published:

2025-11-28

DOI:

10.1038/s41467-025-66667-y

Affiliations:

12

Authors:

29

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	10.833333 10.833333	0.37
Harvard Medical School (HMS), United States of America (USA)	6.666667	0.23
Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), United States of America (USA)	5.166667	0.18
Harvard University, United States of America (USA)	2.000000	0.07
Vanderbilt University Medical Center (VUMC), United States of America (USA)	2.000000	0.07
Agendia Inc. USA, United States of America (USA)	2.000000	0.07
Brigham and Women's Hospital (BWH), United States of America (USA)	0.333333	0.01

Interested in Oncology and Carcinogenesis?